Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer’s Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study

Manuscript Number: 

19-0811R1

Author(s): 
Heii Arai, Alan J.M. Brnabic, Ataru Igarashi, Kristin Kahle-Wrobleski, Kenichi Meguro, Masaru Mimura, Miharu Nakanishi, Masayo Sato, Tamas Treuer, Kaname Ueda, Masahito Yamada

Disclosures

Heii Arai

  • Lecture Fees:
    I have received lecture fees from Eisai, Takeda, Daiichi-Sankyo, Novartis, and Ono, and has received research support from Eisai, MSD, Daiichi-Sankyo, Novartis, Astellas, Dainippon-Sumitomo, Takeda, and Eli Lilly and Company

Alan J.M. Brnabic

  • Equity:
    minor shareholder of Eli Lilly & Company
    Sponsors:
    Full-time employee of Eli Lilly Australia Pty. Limited

Ataru Igarashi

  • Consulting Fees:
    I have received consultant fees from AbbVie, Eli Lilly and Company, Milliman, Novartis Pharma, Novo Nordisk Pharma, and Sony.
    Lecture Fees:
    I have received lecture fees from Bristol-Myers Squibb, Chugai Pharmaceutical, Creativ Ceutical, CRECON Research and Consulting, and Terumo Corporation.
    Grants
    • Agency: 
      Pfizer
      Dates: 
      2015-2017
    • Agency: 
      CSL Behring
      Dates: 
      2015-
    • Agency: 
      Gilead Science
      Dates: 
      2015-
    • Agency: 
      Fuji Film
      Dates: 
      2015-

Kristin Kahle-Wrobleski

  • Equity:
    minor shareholder of Eli Lilly & Company
    Sponsors:
    former employee of Eli Lilly and Company at the time of the GERAS-J Study execution, and currently an employee of Deloitte Consulting LLC

Kenichi Meguro

  • Nothing to Disclose

Masaru Mimura

  • Lecture Fees:
    I have received speaker’s honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly and Company, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin, and research support from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi and Tsumura.

Miharu Nakanishi

  • Consulting Fees:
    consultant fee from Eli Lilly and Company outside of this work

Masayo Sato

  • Equity:
    minor shareholder of Eli Lilly & Company
    Sponsors:
    full-time employee of Eli Lilly Japan

Tamas Treuer

  • Equity:
    minor shareholder of Eli Lilly & Company
    Sponsors:
    Full-time employee of Eli Lilly & Company

Kaname Ueda

  • Equity:
    minor shareholder of Eli Lilly & Company
    Sponsors:
    Eli Lilly Japan

Masahito Yamada

  • Lecture Fees:
    I have received lecture fees from Eli Lilly and Company.
    Grants
    • Agency: 
      Eli Lilly and Company
      Dates: 
      November 29, 2018